Department of Vascular Surgery, The Second Affiliated Hospital of Suzhou University, Suzhou, China.
Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E196-201. doi: 10.1177/1076029610397180. Epub 2011 Mar 14.
Preclinical and clinical studies indicated that endothelial progenitor cells (EPCs) enhanced blood vessel formation in many clinical situations. However, whether transplantation of EPCs would enhance chronic venous thrombus recanalization and resolution is unknown.
Mononuclear cells were isolated from bone marrow of immature rats by density gradient centrifugation, cultured, and then transplanted into inferior vena cava of rats with experimentally induced thrombi. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), messenger RNA (mRNA), and protein expression levels were measured through real-time quantitative polymerase chain reaction and Western blotting of thrombi and adjacent caval walls 14 days following transplantation.
Transplantation of bone marrow-derived EPCs led to an increase in VEGF, bFGF, mRNA, and protein expression. In addition, transplantation of bone marrow-derived EPCs also resulted in reduced thrombus size and increased neovascularization in the specimen.
Transplanted bone marrow-derived EPCs may be a therapeutic option for treating deep venous thrombosis.
临床前和临床研究表明，内皮祖细胞（EPCs）可促进多种临床情况下的血管生成。然而，EPC 移植是否会增强慢性静脉血栓再通和溶解尚不清楚。
通过密度梯度离心法从未成年大鼠的骨髓中分离出单核细胞，培养后移植到实验性血栓形成的大鼠下腔静脉中。通过实时定量聚合酶链反应和血栓及相邻腔壁的 Western 印迹检测移植后 14 天的血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）、信使 RNA（mRNA）和蛋白表达水平。
骨髓源性 EPC 移植导致 VEGF、bFGF、mRNA 和蛋白表达增加。此外，骨髓源性 EPC 移植还导致标本中的血栓体积减小和新生血管增加。
移植的骨髓源性 EPC 可能是治疗深静脉血栓的一种治疗选择。
